ZURICH, Oct. 21, 2007 (Thomson Financial delivered by Newstex) -- Novartis (NYSE:NVS) AG continues to strengthen its biotech unit and might consider acquisitions in the segment, chief executive Daniel Vasella said in an interview with Swiss bi-weekly Finanz und Wirtschaft.'We have strengthened the segment internally. We also have various co-operations with biotech companies...The future will show whether acquisitions will be necessary,’ Vasella said.
